Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors
Open Access
- 1 June 2021
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8), bvab100
- https://doi.org/10.1210/jendso/bvab100
Abstract
Context Immune checkpoint inhibitors (ICIs) have gained a revolutionary role in management of many advanced malignancies. However, immune-related endocrine events (irEEs), have been associated with their use. irEEs have nonspecific clinical presentations and variable timelines, making their early diagnosis challenging. Objective To identify risk factors, timelines, and prognosis associated with irEEs development. Design and Setting Retrospective observational study within the Cleveland Clinic center. Patients Metastatic cancer adult patients who received ICIs were included. Methods 570 charts were reviewed to obtain information on demographics, ICIs used, endocrine toxicities, cancer response to treatment with ICI, and overall survival. Main Outcome Measures Incidence of irEEs, time to irEEs development and overall survival of patients who develop irEEs. Results The final cohort included 551 patients. The median time for the diagnosis of irEEs was 9 weeks. Melanoma was associated with the highest risk for irEEs (31.3%). Ipilimumab appeared to have the highest percentage of irEEs (29.4%), including the highest risk of pituitary insufficiency (11.7%), the most severe (Grade 4 in 60%) and irreversible (100%) forms of irEEs. Forty-five percent of patients with irEEs had adequate cancer response to ICI compared to 28.3% of patients without irEEs (P = 0.002). Patients with irEEs had significantly better survival compared to patients without irEEs (P < 0.001). Conclusions In the adult population with metastatic cancer receiving treatment with ICI, irEEs development may predict tumor response to immunotherapy and a favorable prognosis. Ipilimumab use, combination ICI therapy, and melanoma are associated with a higher incidence of irEEs.Keywords
This publication has 40 references indexed in Scilit:
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1Cancer Research, 2012
- Membrane Receptor for Thyroid Hormone: Physiologic and Pharmacologic ImplicationsAnnual Review of Pharmacology and Toxicology, 2011
- Pharmacodynamic Modeling of Anti-Cancer Activity of Tetraiodothyroacetic Acid in a Perfused Cell Culture SystemPLoS Computational Biology, 2011
- Adjuvant Therapy With Agonistic Antibodies to CD134 (OX40) Increases Local Control After Surgical or Radiation Therapy of Cancer in MiceJournal of Immunotherapy, 2010
- Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)Cell Cycle, 2009
- Hypothyroidism in older patients with head and neck cancer after treatment with radiation: A population‐based studyHead & Neck, 2009
- Acting via a Cell Surface Receptor, Thyroid Hormone Is a Growth Factor for Glioma CellsCancer Research, 2006
- Thyroid hormone and breast carcinomaCancer, 2005
- Relationship of thyroid disease to renal cell carcinoma An epiden ologic studyUrology, 1990
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsThe New England Journal of Medicine, 1988